FierceBiotech 2026년 6월 2일 Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
FDA News Releases 2026년 6월 2일 FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
FierceBiotech 2026년 6월 2일 ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech 2026년 6월 2일 ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
FierceBiotech 2026년 6월 2일 MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
Novartis 2026년 6월 2일 ASCO26: Celcuity's drug halves risk of disease progression, death versus Novartis' Piqray in PIK3CA-mutant breast cancer - FirstWord Pharma
Endpoints News 2026년 6월 2일 #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout